A Phase I, Randomised, Open-Label, Cross-Over, Single Centre Study in Healthy Volunteers to Determine the Relative Bioavailability of the Phase III Tablet Formulation to the Phase II Tablet Formulation of AZD0530.
Phase of Trial: Phase I
Latest Information Update: 19 Jun 2009
At a glance
- Drugs Saracatinib (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 10 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 10 Jun 2009 Actual patient number (18) added as reported by ClinicalTrials.gov.